This article traces the evolution of API-in-capsule (AIC) technology, from its early disruption of traditional formulation through the Xcelodose® system, to its reinvention in 3P innovation’s Fill2Weight platform. The authors explore how AIC has shifted from a risky bet to a scalable solution for modern drug development. Looking ahead, they highlight the transformative role AIC can play in personalised medicine, oncology, and DPI, where flexibility and precision are key to success.
Authors: